Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says

This article was originally published in The Pink Sheet Daily

Executive Summary

A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.

You may also be interested in...



SSRI Advisory Committee

FDA "has not yet made a final determination on the need for an advisory board on suicidality in adults" using selective serotonin reuptake inhibitors, Johnson & Johnson says

SSRI Advisory Committee

FDA "has not yet made a final determination on the need for an advisory board on suicidality in adults" using selective serotonin reuptake inhibitors, Johnson & Johnson says

Antidepressant MedGuide Distribution Imminent; Unit-Of-Use Packs To Follow

The new patient Medication Guide is expected to reach pharmacies the week of March 7. The standardized MedGuides will be issued as tear-off pads for about a year until manufacturers implement unit-of-use packaging, which would allow the guide to be pre-packaged with every prescription.

Related Content

Topics

UsernamePublicRestriction

Register

PS062281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel